Journal Reading

2025/04/23

Clerk: 黃昱穎

Supervisor: 鄭評嘉醫師

Revised: 6 January 2024

Accepted: 5 February 2024

DOI: 10.1002/alr.23339

CLINICAL LETTER




Severe epistaxis after posterior nasal nerve ablation requiring surgical intervention: A multi-center case series

- Chronic rhinitis affects ~33% of the U.S. population
- Symptoms: sneezing, nasal congestion, rhinorrhea
- PNN ablation: emerging office-based treatment
- Targets parasympathetic nerves to decrease submucosal gland secretion, blood flow, and stromal edema
- FDA-approved devices:
 - Cryotherapy: ClariFix
 - Radiofrequency: RhinAer, Neuromark
 - → Symptom burden significant improvement 70-100%


PNN ablation


- Etiology of non-allergic rhinitis: arise from a dysfunction of sympathetic and parasympathetic innervation
- Medical therapy failure→ surgery
 - Vidian nerve (VN) neurectomy: notably eye dryness
 - Posterior nasal nerve (PNN) neurectomy: fewer adverse effects, but unsatisfactory symptom resolution
- Recently, posterior nasal nerve (PNN) ablation has emerged as a popular option


Background Anatomy



Cryotherapy











3.B

3.C

Radiofrequency





Purpose of Study

- Evaluate incidence of severe epistaxis after PNN ablation
- Analyze patient demographics and outcomes
- Provide guidance on patient counseling and risk management

Material and Method


- Retrospective review: June 2018 August 2023
- Settings: 2 tertiary centers, 1 private practice
- Total patients: 461

Result

Overview

- 11/461 patients (2.4%) had severe epistaxis
- Mean onset: 20 days post-op (13–24 days)
- No significant differences by device type
 - ClariFix: 2.7%
 - RhinAer: 1.9%
 - Neuromark: 1 case
- SPA involvement in all severe epistaxis cases

Result



Total no. of patients 461 450 11

Age (median [IQR]) 66 [61, 74] 66.00 [51, 74] 57 [45, 68.50]

Sex (%)

Male 234 (50.8) 228 (50.7) 6 (54.5)

Female 226 (49.0) 221 (49.1) 5 (45.5)

287 (62.4)

30 (6.5)

143 (31.1)

93 (20.2)

263 (57)

192 (41.5)

3(0.7)

3(0.7)

Abbreviations: IQR, interquartile range; POD, postoperative day; SD, standard deviation; SPA, sphenopalatine artery.

Demographics of patients who underwent posterior nasal nerve (PNN) ablation.

No epistaxis

228 (50.7)

210 (46.7)

89 (19.8)

279 (62.1)

28 (6.2)

142 (31.6)

89 (19.8)

258 (57.6)

187 (41.6)

2(0.4)

3(0.7)

Epistaxis requiring intervention

6 (54.5)

8 (72.7)

3 (27.3)

8 (72.7)

2(18.2)

1(9.1)

4 (36.4)

5 (45.5)

5 (45.5)

1(9.1)

0

19.64 (3.78)

2 (18.2)

7 (63.5)

2 (18.2)

p value

0.260

1

0.160

0.816

0.688

0.333

0.206

0.330

0.634

0.104

Overall

Age (median [IQR]) 66 [61, 74]

Sex (%)

Male 234 (50.8)

Female 226 (49.0)

Comorbidities (%)

Allergies 234 (50.8)

Hypertension 218 (47.3)

Diabetes 92 (20)

Tobacco use (%) Never

Current

Former

Rhinaer

Clarifix

Neuromark

Embolization

SPA ligation

Cauterization

Anticoagulation therapy (%)

Method of ablation (%)

Rhinaer and Clarifix

POD of epistaxis onset (mean (SD))

Method of operative intervention (%)

Result

Intervention

- 7 patients: SPA ligation
- 2 patients: Embolization
- 2 patients: Cauterization
- No recurrent bleeding reported after intervention

Summary of patients with significant epistaxis after posterior nasal nerve (PNN) ablation requiring surgical intervention. Allergies HTN Device POD Intervention Sex Tobacco AC DMNotes Age Never Ν Ν RhinAer 21 Embolization Bilateral SPA Presented to OSI with bilateral epistaxis. 50 Never Ν Y Y Neurent 20 ligation Never Y Ν Y Y ClariFix 24 Cauterization Presented with right-sided epistaxis that persisted despite Merocel packing and subsequently inflatable balloon catheter use. Embolization Never Y Ν N RhinAer 18 Y Y Unilateral SPA Presented to OSI with bilateral epistaxis, Ν RhinAer 17 70 Current ligation bilateral rhinorockets were placed and Age: 33–89 yrs, both transferred to higher level of care Never Ν Ν Ν Ν RhinAer 22 Unilateral SPA Presented to OSI with right-sided F epistaxis, right rhinorocket was placed ligation and blood transfusion was given. Most non-smokers Current Y Y Ν ClariFix 23 Unilateral SPA Presented with persistent epistaxis despite two attempts of absorbable ligation nasal packing. ClariFix 14 Unilateral SPA Present with unilateral epistaxis, Former Y Ν Ν identified in office as SPA and treated ligation in OR ClariFix 24 Cauterization Presented with intermittent high volume 51 M Never Y Y Y Y epistaxis despite bioabsorbable nasal packing. Site identified and treated in office Never Y Y Y N ClariFix 20 Unilateral SPA Presented to OSI with unilateral epistaxis, ligation persistent despite rhinorocket. Transferred for SPA ligation Never Y Ν RhinAer 13 Unilateral SPA Presented to OSI with unilateral epistaxis, bilateral rhinorockets, intubation, ligation multiple unit blood transfusion followed by SPA ligation Abbreviations: AC, anticoagulation; DM, diabetes; HTN, hypertension; OSI, outside institution; POD, postoperative day; SPA, sphenopalatine artery.

- sexes affected

- Majority required SPA ligation
- Several cases
- needed transfusion, intubation, or referral to tertiary care

Discussion

- Minor side effects previously reported (pain, headache)
- Delayed epistaxis (~3 weeks post-op) may be due to:
 - SPA pseudoaneurysm or weakening of the SPA wall
 - Vascular remodeling
- Similar to post-tonsillectomy hemorrhage timing
- Need for clear preoperative counseling

Implications & Future Direction

- Although rare, serious bleeding should be anticipated
- Physicians should be equipped to manage late epistaxis
- Encourage:
 - Biopsy or imaging to explore etiology
 - Studies identifying patient/device-specific risks

Conclusion

- PNN ablation is a safe procedure for the treatment of recalcitrant chronic rhinitis
- Severe epistaxis is rare but significant
- Enhanced informed consent and follow-up planning are recommended

Thank you for your attention